Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEKTRA: TAK-935 as Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies
NCT03650452Phase 2Completed
- Sponsor
- Takeda
- Start
- Aug 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in Dravet syndrome and Lennox-Gastaut syndrome (LGS) comparing Placebo with TAK-935 (2 arms). Primary endpoint: Percent Change From Baseline in Seizure Frequency Per 28 Days. Started Aug 2018; status: completed.
02
Drugs
soticlestat
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT03650452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03650452.